Crispr Therapeutics AG (CRSP) — Cash Flow Quality Index
Crispr Therapeutics AG (CRSP) has a Cash Flow Quality Index of -1.08x as of December 2023. Operating cash flow of $-96.07 Million is below net income of $89.35 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore cash flow conversion of Crispr Therapeutics AG to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Crispr Therapeutics AG Cash Flow Quality Index (2019–2021)
Historical Cash Flow Quality Index for Crispr Therapeutics AG across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Crispr Therapeutics AG (CRSP) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Crispr Therapeutics AG (2019–2021)
Year-by-year earnings quality comparison for Crispr Therapeutics AG. For live market cap and the full company financial profile, see Crispr Therapeutics AG (CRSP) market capitalisation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2021 | 1.43x | $538.97 Million | $377.66 Million | ▲ +68.3% |
| 2019 | 0.85x | $56.68 Million | $66.86 Million | — |